How Vibe Bio treats what big pharma ignores �� 

When biochemist Alok Tayi’s daughter was diagnosed with a rare disease, he faced a harsh truth: the drug could be developed — but no one would fund it. The market was too small, the profits too low. Millions of patients face the same trap

That’s why Vibe Bio was born — a DAO where patients, doctors, and researchers team up to launch the treatments they actually need. Everything runs through the $VIBE token:

 Any member can propose a disease to prioritize
 The community votes on which proposals matter most
 Winners get funding and spin off as biotech startups
 If a treatment reaches the market, profits flow back to the DAO and its members

The project has already raised $12M from Balaji Srinivasan, Naval Ravikant, and Pfizer Ventures. First initiatives target rare metabolic and autoimmune diseases

Unlike traditional pharma — where decisions serve investors — Vibe Bio puts power in the hands of the patients. It turns people from passive bystanders into co-creators of the future of medicine